COMUNICADO: Un estudio muestra la correlación entre un subtipo de cancer de pulmón y los resultados del tratamiento (y 2)

    
    (1) Peterson P, Park K, Fossella F, et al. Is Pemetrexed More Effective
        in Adenocarcinoma and Large Cell Lung Cancer than in Squamous Cell
        Carcinoma? A Retrospective Analysis of a Phase III Trial of
        Pemetrexed vs Docetaxel in Previously Treated Patients with Advanced
        Non-small Cell Lung Cancer (NSCLC). Abstracto # 6521, 14 Conferencia
        Europea Sobre el Cáncer (ECCO).
    (2) Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial
        of pemetrexed versus docetaxel in patients with non-small cell lung
        cancer previously treated with chemotherapy. J Clin Oncol 2004;
        22:1589-97.
    (3) Sigmond J Backus HH, Wouters D, et al. Induction of resistance to the
        multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon
        cancer cells is associated with thymidylate synthase overexpression.
        Biochem Pharmacol 2003; 66:431-38.
    (4) Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the
        lung compared to other histotypes shows higher messenger RNA and
        protein levels for thymidylate synthase. Cancer 2006; 107:1589-96.
    (5) National Cancer Institute, "General Information About Non-Small Cell
        Lung Cancer", Modificado el 2 de agosto de 2007.
        http://www.cancer.gov/cancertopics/pdq/treatment/
        non-small-cell-lung/patient
        (Acceso desde el 11 de septiembre de 2007).
    (6) American Cancer Society, "What is non-small cell lung cancer?",
        Modificado el 25 de octubre de 2006.
        http://www.cancer.org/docroot/CRI/
        content/CRI_2_4_1x_What_Is_Non-Small_Cell_Lung_Cancer.asp?sitearea=
        (Accessed Sept. 18, 2007).
    (7) Okabe T, Nakagawa K, Kuboto K, et al. Prognostic factors affecting
        survival on pretreated patients with locally advanced or metastatic
        non-small cell lung cancer (NSCLC) - Subgroup analysis in a
        randomized Ph. II study of pemetrexed 500 mg/m2 and 1000 mg/m2.
        Abstract # P-6560, 14th European Cancer Conference.
    (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

Gregory L. Clarke de Eli Lilly and Company, + 1-317-554-7119 (móvil), gregory.clarke@lilly.com; o Paul George de CPR Worldwide, +1-917-251-1038 (móvil), p.george@cprworldwideusa.com, para Eli Lilly and Company /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, photodesk@prnewswire.com